AI assistant
Sending…
RELMADA THERAPEUTICS, INC. — Director's Dealing 2020
Nov 3, 2020
34465_dirs_2020-11-03_1039fa01-ad97-492e-a72e-fc452ae6eb3a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2020-11-02
Reporting Person: CASAMENTO CHARLES J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-11-02 | Common Stock | S | 3000 | $30.2879 | Disposed | 49173 | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $30.00 to $31.33. The average weighted price was $30.2879. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
More from RELMADA THERAPEUTICS, INC.
Declaration of Voting Results & Voting Rights Announcements
2026
May 28
Share Issue/Capital Change
2026
May 13
Regulatory Filings
2026
May 12
Capital/Financing Update
2026
Apr 9
Regulatory Filings
2026
Mar 20
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 12
Capital/Financing Update
2026
Jan 30
Director's Dealing
2025
Dec 16